Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Addition of aprepitant, an NK1 receptor antagonist to a 5-HT3 receptor antagonist and
dexamethasone regimen was shown to be effective for prevention of chemotherapy-induced nausea
and vomiting (CINV) with moderately emetogenic chemotherapy (MEC). Little is known about the
efficacy of aprepitant when used without dexamethasone. Dexamethasone is widely used to
prevent both acute and delayed nausea and vomiting induced by chemotherapy. However,
multi-period use of dexamethasone could be associated with side effect, such as
hyperglycemia, dyspepsia and insomnia. This randomized phase III trial studies antiemetic
therapy with aprepitant and tropisetron to see how well they work compared to dexamethasone
plus tropisetron in preventing chemotherapy-induced nausea and vomiting in patients with
colorectal cancer receiving FOLFOX(oxaliplatin, leuvovorin and 5-fluorouracil) chemotherapy.